1
EXHIBIT 10.23
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT
BETWEEN
COMBICHEM, INC.
AND
ATHENA NEUROSCIENCES, INC.
OCTOBER 15, 1997
2
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the
"Agreement") is entered into and made effective as of October 15, 1997 (the
"Effective Date"), by and between COMBICHEM, INC., a Delaware corporation having
its principal offices at 0000 Xxxxxx Xxxxx Xx, Xxx Xxxxx, Xxxxxxxxxx 00000
("CombiChem") and ATHENA NEUROSCIENCES, INC., a Delaware corporation and a
wholly-owned subsidiary of Elan Corporation, plc ("Elan"), having its principal
offices located at 000 Xxxxxxx Xxxxxxxxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000
("Athena").
WHEREAS, CombiChem has developed and owns certain drug discovery
technology and intellectual property rights, including chemical library design
software, multi-parallel synthesis and purification methods, chemical libraries
suitable for high throughput biological screening assays and medicinal chemistry
(collectively, "CombiChem Technology");
WHEREAS, as of the Effective Date, Elan, Athena and their
Affiliates have developed and own certain drug discovery and intellectual
property rights, including certain assays, methods and know how regarding the
Initial Targets and the Optional Targets, among other things (collectively
"Athena Technology");
WHEREAS, Athena desires to utilize CombiChem Technology for its
drug discovery activities under Athena know-how concerning the identification
and characterization of novel small molecule inhibitors for development as
therapeutics for treatment of central nervous system conditions in humans;
WHEREAS, the parties wish to collaborate in a Research Program
against Collaboration Target(s) ("Collaboration");
WHEREAS, during the Research Period and for purposes of the
Collaboration, the Parties intend to focus on up to six (6) Collaboration
Targets;
NOW, THEREFORE, the Parties agree as follows:
1. DEFINITIONS
1.1 "Abandoned Target" shall have the meaning given in Section
4.1.
1.2 "Abandoned Compound" shall have the meaning given in Section
4.1.
1.3 "Active Compound(s)" means a compound (or compounds) which
(a) (i) is selected by the RMC under the Research
Program from Collaboration Compounds under
Section 4.2, or
1
3
(ii) is a Derivative of a Collaboration Compound
which is so selected by the RMC; and
(b) shows In Vitro Activity.
1.4 "Affiliate" of a Party means any corporation or other
business entity controlled by, controlling or under common control with, such
Party. For this purpose "control" shall mean direct or indirect beneficial
ownership of more than fifty percent (50%) of the voting securities or income
interest in such corporation or other business, or if not meeting the preceding
requirements, any company owned or controlled by or owning or controlling such
Party at the maximum control or ownership right permitted in the country where
such company exists.
1.5 "Athena Compound" means a chemical compound that is
proprietary to Athena or whose use or manufacture is proprietary to Athena or
its Affiliates.
1.6 "Athena Technology" shall have the meaning set forth in the
preamble of this Agreement.
1.7 "Collaboration" has the meaning set forth in the preamble.
1.8 "Collaboration Compound(s)" means a compound (or compounds)
which (a) is synthesized following the Effective Date for screening against a
Collaboration Target under the Research Program, (b) is a pre-existing or
hereafter acquired CombiChem compound which CombiChem desires to designate as a
Collaboration Compound, or (iii) is a pre-existing or hereafter acquired Athena
compound which Athena desires to designate as a Collaboration Compound.
1.9 "Collaboration Library" means a library synthesized under the
direction of the RMC, containing compounds designed to provide information
regarding activity against a specific Collaboration Target.
1.10 "Collaboration Target(s)" means either an Initial Target or
an Optional Target.
1.11 "CombiChem Compound" means a chemical compound that is
proprietary to CombiChem, or whose use or manufacture is proprietary to
CombiChem.
1.12 "CombiChem Technology" has the meaning set forth in the
preamble.
1.13 "Confidential Information" includes, but is not limited
to,
(a) all information and materials received by either
Party from the other Party pursuant to this
Agreement which is confidential under Article 11;
2
4
(b) all information and materials by either Party
arising out of the Collaboration during the
Research Period;
(c) all Daughter Libraries, excluding Inactive
Compounds and Returned Compounds; and
(d) the financial terms of this Agreement.
1.14 "Daughter Libraries" shall mean the compound libraries which
are designed and synthesized as a part of the Collaboration.
1.15 "Derivative" shall mean a compound (or compounds) which has
resulted from subsequent chemical synthesis to generate an Active Compound or
Development Compound in support of the Research Program.
1.16 "Development Compound(s)" means a compound (or
compounds) which
(a) (i) is an Active Compound or (ii) is a
Derivative of an Active Compound; and
(b) is determined by Athena to be appropriate for
preclinical studies for the purpose of IND filing
by Athena.
1.17 "Due Diligence" means the use of by a Party of its or its
Affiliates' resources in a manner which is consistent with the exercise of
reasonable and prudent scientific and business judgment as applied to other
programs of Athena or CombiChem, as the case may be, targeting products aimed at
markets or patient groups of similar sizes and of similar scientific and
commercial potential. With respect to any Development Compound, "Due Diligence"
shall also require Athena or its Affiliates to use commercially reasonable
efforts to conduct all necessary preclinical studies and to file an IND for such
Development Compound within two (2) years from the date upon which Athena has
designated such Development Compound from any Active Compound or its
Derivatives. For purposes of this Agreement, failure to exercise Due Diligence
by any Party shall be established if such Party receives written notice
describing such failure and does not cure such failure within ninety (90) days
of the receipt of such notice.
1.18 "Exclusivity Period" means the Research Period plus
twelve (12) months.
1.19 "Field" means all therapeutic and diagnostic indications in
humans for any target against which an Active Compound, Development Compound or
Products may be directed.
1.20 "First Commercial Sale" of a Product shall mean the first
sale for use or consumption of such Product in a country after required
marketing and pricing approval has been granted by the governing health
regulatory authority of such country. Sale to an Affiliate shall not constitute
a First Commercial Sale unless the Affiliate is the end user of the Product.
3
5
1.21 "FTE" shall mean a full-time equivalent employee of
CombiChem. For purposes of this Agreement, the FTEs shall include synthetic and
analytical chemists, compound control scientists and computational scientists.
1.22 "Inactive Compound(s)" means a Collaboration Compound(s)
which does not have the In Vitro Activity required for an Active Compound.
1.23 "In Vitro Activity" shall mean the observation of *** in
assays as described by Athena in the Research Plan for each Collaboration
Target.
1.24 "Initial Target" shall have the meaning set forth in
Section 3.1 hereof.
1.25 "Net Sales" means the gross sales invoiced by Athena or its
Affiliates for Products to non-Affiliated Third Parties (and to Affiliates who
are the end users of such Products) less actual deductions or returns (including
withdrawals and recalls), rebates (price reductions, including formulary or
Medicaid and similar types of rebates, e.g. chargebacks), cash, trade or volume
(quantity) discounts, discounts granted at the time of invoicing, the cost of
transport, insurance, delivery, sales taxes and use, tariff, excise or other
taxes (other than income taxes) directly linked to and included in the gross
sales amount as computed on a product-by-product basis for the countries
concerned, whereby the amount of such sales in foreign currencies is converted
into United States dollars at the exchange rate of the last business day for
each calendar month as reported in The Wall Street Journal.
1.26 "Optional Target(s)" means a Target that is added to the
Collaboration in accordance with Section 3.2.
1.27 "Patent" means (a) valid and enforceable Letters Patent, and
any non-U.S. equivalent, including any extension (including Supplemental
Protection Certificates), registration, confirmation, reissue, continuation,
divisionals, continuation-in-part, reexamination or renewal thereof, or (b)
pending applications for any of the foregoing, whether filed or issued before or
after the Effective Date of this Agreement.
1.28 "Party" means CombiChem or Athena, as the case may be,
including their respective Affiliates, permitted successors and assigns.
1.29 "Product(s)" means any product containing an Active Compound
or Development Compound with such compound as the active ingredient and which is
granted regulatory approval by the governing health regulatory authority of the
applicable country for marketing in the Field.
1.30 "Project Team" shall have the meaning set forth in Section
2.1(c).
1.31 "Proposed Targets" shall have the meaning given in Section
3.1.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
4
6
1.32 "Related Target(s)" shall mean those targets identified by
Athena in writing to CombiChem as having a direct relationship to Collaboration
Targets or Proposed Targets, which will provide Athena exclusivity as outlined
in Section 4.5.
1.33 "Research Management Committee" or "RMC" has the meaning set
forth in Article 6 below.
1.34 "Research Period" means the initial term of the
Collaboration commencing on the Effective Date and ending on December 31, 2000,
unless earlier terminated, which can be extended in accordance with Section 7.1
below.
1.35 "Research Plan" means the research plan to be agreed in
writing between the Parties, which describes the research activities to be
performed for each Collaboration Target.
1.36 "Research Program" means the research to be conducted for
the Collaboration including, without limitation, the activities described in the
Research Plan and set forth in Sections 2.1 and 2.2 of this Agreement.
1.37 "Returned Compound" shall have the meaning set forth in
Section 9.2.
1.38 "Royalty Term" means, in the case of any Product, in any
country, the period of time commencing on the First Commercial Sale and ending
upon the later of (a) ten (10) years from the date of First Commercial Sale in
such country; or (b) the expiration of the last-to-expire Patent resulting from
the Research Program filed in the Field during the Exclusivity Period with
claims covering that Product in the relevant country.
1.39 "Target" means a biomolecular entity that a small molecule
is synthesized against wherein the small molecule demonstrates relevant
activity.
1.40 "Territory" means the entire world.
1.41 "Third Party" means an entity other than CombiChem or Athena
or their respective Affiliates.
1.42 "UIL" means CombiChem's proprietary Universal Informer
Library(TM).
2. RESEARCH COLLABORATION
2.1 CombiChem Responsibilities. CombiChem shall with Due
Diligence provide the following resources to Athena and conduct the following
activities under the Research Program and as more fully described in the
Research Plan:
(a) During the Research Period, CombiChem shall (i)
review data and information regarding the
Collaboration Targets provided by Athena; (ii)
based on such data and information and using the
5
7
CombiChem Technology, design Daughter Libraries;
and (iii) supply all lead chemistries and
synthesize compounds as provided in Section 5.4
below.
(b) During the Research Period, CombiChem shall keep
Athena informed of its activities performed in
connection with the Collaboration, including,
without limitation, providing Athena with data and
information (and, upon Athena's request, reasonable
quantities of samples pursuant to Section 5.4)
regarding the status of all Collaboration Compounds
prior to the meetings of the Research Management
Committee.
(c) Subject to Section 2.3, Article 3 and Section 8.3,
and at all times during the Research Period,
Combichem shall dedicate, in separate laboratory
facilities as to its chemistry efforts, one or more
project team(s) ("Project Team"), each consisting
of such number of FTEs as determined by the RMC to
conduct all of CombiChem's activities in connection
with the collaboration at a per annum rate of U.S.
*** to be paid by Athena. The initial Project Team
shall consist of a minimum of five (5) CombiChem
FTEs, unless the RMC determines other use.
2.2 Athena Responsibilities. Athena shall with Due Diligence
provide the following resources to CombiChem and conduct the following
activities under the Research Program as more fully described in the Research
Plan:
(a) Athena shall provide CombiChem with funding for the
Collaboration as set forth in Article 8, provide
screening, biological and structural data and
information (including leads and/or screening hits
and assay methods relating to Collaboration
Compounds) to CombiChem with respect to the
Collaboration necessary for CombiChem to perform
its duties under this Agreement, and will assume
scientific, financial and administrative
responsibility for screening and biological support
activities, drug development and regulatory filings
during and after the term of the Collaboration on
the terms set forth below. At its option, Athena
may also provide pre-existing screening data and
related information for the Collaboration.
(b) During the Research Period, Athena shall provide
CombiChem with data and information regarding
Collaboration Compounds and the Collaboration
Target assays developed by Athena under the
Research Program prior to the meetings of the
Research Management Committee.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
6
8
(c) During the Exclusivity Period, Athena shall screen
Collaboration Compounds for In Vitro Activity and,
where appropriate, in vivo activity against the
Collaboration Target.
(d) During the Exclusivity Period, with respect to any
Collaboration Target against which an Active
Compound has designated by the RMC, Athena shall
(i) screen Active Compound, (ii) endeavor to
determine Development Compounds, and (iii) endeavor
to develop Products. At any time during the
Collaboration, Athena may apply chemistry effort to
any Collaboration Compound, including synthesis, as
coordinated by the RMC.
(e) Following the first IND filing through First
Commercial Sale, Athena shall provide CombiChem
with an annual report summarizing Athena's
activities in developing Development Compounds.
2.3 Conduct of Research Program. The Parties hereby agree that
the Research Programs shall be carried out in accordance with the Research Plan,
as amended from time to time. The Research Management Committee shall review the
Research Plan on an ongoing basis and may make changes to the Research Plan so
long as such changes are mutually agreed to by CombiChem and Athena. For each
Research Program, the RMC will determine the appropriate size and composition of
the Project Team (i.e., the identity and number of CombiChem FTEs in each
relevant scientific discipline), and shall prioritize the activities of the
Project Team against such Collaboration Target(s) within the scope of that
Research Program.
Athena shall designate the first Collaboration Target from
the Proposed Targets by notice in writing to CombiChem. The Research Program
against that Target shall commence *** against the *** Collaboration Target. The
commencement date of the Research Program(s) for the subsequent Initial Targets
(other than the first Collaboration Target) and any Optional Targets shall be as
set forth in Section 3.1.
2.4 Third Party Licenses. Each Party shall be solely responsible
for any Third Party license fees required to perform its obligations under this
Agreement.
3. TARGETS
3.1 Initial Targets. During the Research Period, Athena may
designate *** "Proposed Targets" (with the right of substitution) as "Initial
Targets" to be worked on by Project Teams for purposes of the Collaboration. The
Proposed Targets and the Initial Targets shall be those designated in writing by
the Chief Operating Officer of Elan within *** of the Effective Date. No
activity with respect to any Initial Targets shall be conducted by the Project
Teams until a date to be mutually agreed upon by the Parties. The Project Teams
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
7
9
shall work on Initial Targets as directed by the RMC. The project fee set forth
in Section 8.1(a) shall include all *** Initial Targets.
3.2 Optional Targets. Subject to timely payment of its
obligations set forth in Article 8 (including the project initiation fee set
forth in Section 8.1(b) and the payments required in Sections 8.3, 8.4, 8.5 and
9.3) and provided that all *** Initial Targets have been designated by Athena
and the Research Programs covering such Initial Targets are or have been active,
during the Research Period, Athena may designate (by providing written notice in
the manner described in Section 3.1) *** additional Proposed Targets (or other
Targets as may be mutually agreed) as Optional Targets, with the Research
Program for each such Optional Target to begin within ninety (90) days of such
written notification or as mutually agreed by the parties; it being understood
that the Project Teams shall work on Optional Targets as directed by the RMC.
The project initiation fee set forth in Section 8.1(b) shall include ***
Optional Targets. Upon such designation, the RMC shall establish the specific
scientific achievements (to be mutually agreed between CombiChem and Athena) for
such Optional Target and the same shall be designated as an Optional Target for
the Collaboration and subject to the terms (including the commercial terms) of
this Agreement.
4. EXCLUSIVITY
4.1 Collaboration Target Exclusivity. Prior to designating a
Collaboration Target for an active Research Program under Article 3, and
thereafter so long as Athena or its Affiliates are proceeding with Due Diligence
for that Target, CombiChem shall not knowingly work on or knowingly provide
information regarding a Collaboration Target with or to any Third Parties,
except (a) as provided for in Section 12.2 with regard to any Public Statements,
and (b) with respect to any Third Parties who are collaborators or proposed
collaborators of CombiChem, CombiChem shall have the right, consistent with its
corporate policy (but without identifying any Collaboration Target), to notify
any such Third Party of its decision and/or inability to work on such Target
with that Third Party. In the event that Athena or its Affiliates have not
transferred or assigned control of its program for that Target to a Third Party
under due diligence obligations no less stringent than those set forth herein
and have failed to exercise Due Diligence with respect to, or notifies CombiChem
in writing that it has abandoned work on, any Collaboration Target (an
"Abandoned Target") and any Collaboration Compound associated with such
Abandoned Target (together with all Derivatives of such Collaboration Compound,
an "Abandoned Compound"), then such Abandoned Target and/or Abandoned Compound
shall be available to CombiChem (excluding any Athena Compounds and Athena
Technology) and to Athena for any purpose thereafter.
4.2 Active Compounds. Following the designation of any
Collaboration Compound as an Active Compound, such Active Compound shall be
exclusively available to Athena for research or application to any Target,
within or outside the Collaboration, during the Exclusivity Period and CombiChem
shall not knowingly work on or knowingly provide information regarding such
Active Compound to any Third Party, except to reject and take any steps
necessary to protect Athena's exclusivity hereunder. Following the expiration of
the Exclusivity Period Active Compounds for that Target upon which a Patent has
not been filed
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
8
10
within ninety (90) days following the Research Period shall be deemed to be
Inactive Compounds for all purposes hereunder; provided, that any Active
Compound which is the subject of claim(s) under a pending Patent shall continue
to be treated as Active Compounds until a Patent is issued with respect to one
or more of such claims; or until all of such Patent claims have been denied, at
which time the compounds which are the subject to those claims shall be Inactive
Compounds hereunder.
4.3 Inactive and Returned Compounds. Any Inactive Compounds and
Returned Compounds shall be available to CombiChem (except for any pre-existing
Athena Compound) and Athena for any purpose following the designation of a
Collaboration Compound as an Inactive Compound or Returned Compound.
4.4 Duration of Exclusivity for Collaboration Targets.
Notwithstanding any other provision of this Agreement, it is understood and
agreed that once a research Program has been initiated by the RMC for a
Collaboration Target, CombiChem's obligations under Section 4.1 shall continue
until Athena has (a) released CombiChem from the effect of this Section 4.4 by
written notice from the Chief Operating Officer of Elan, or (b)(i) failed to
exercise Due Diligence with respect to that Target, and (ii) has not transferred
or assigned its control of the development of its program for that Target to a
Third Party with due diligence requirements no less stringent than those set
forth in this Agreement. In the event of such transfer or assignment to a Third
Party, the Exclusivity Period provided in this Section 4.4 with respect to such
Target shall continue until the earlier of (a) receipt by CombiChem of a written
release from such Third Party or (b) the failure of such Third Party to exercise
Due Diligence with respect to that Target.
4.5 Exclusivity of Related Targets. (a) During the Research
Period (and thereafter, as provided in Section 4.5(c) below), CombiChem shall
not knowingly work on or knowingly provide information regarding a Related
Target with or to any Third Party, except (i) as provided for in Section 12.2
with regard to any Public Statements, and (ii) with respect to any Third Parties
who are collaborators or proposed collaborators of CombiChem, CombiChem shall
have the right, consistent with its corporate policy (but without identifying
any Collaboration Target or Related Target) to notify any such Third Party of
its decision and/or inability to work on such Target with that Third Party.
(b) *** *** has conducted scientific inquiry or research
regarding that Target. The RMC may from time to time discuss the status
of Athena's inquiry or research into any such additional Related
Targets. Athena shall notify CombiChem in writing if it abandons its
inquiry or research regarding any additional Related Targets, at which
point it shall no longer be a Related Target.
(c) The exclusivity provided in Section 4.5(a) shall be
extended for an additional year following the Research Period upon the
initiation of a Research Program for each of the *** Collaboration
Targets, for a maximum extension of three years following the Research
Period.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
9
11
(d) If a Related Target or additional Related Target
becomes a Collaboration Target, then all of the other provisions of
this Agreement (including without limitation the exclusivity provisions
of this Article 4) shall apply to such Collaboration Target.
4.6 Survival. This Article 4 shall survive termination or
expiration of this Agreement.
5. COLLABORATION COMPOUNDS
5.1 Pre-Existing Compounds. Neither Party shall have any rights
to any pre-existing compound of the other Party unless and until such compound
is designated as a Collaboration Compound by such Party. Additionally, CombiChem
may decline (after informing Athena) to synthesize a particular compound or
library of compounds by reason of existing Patents or contractual obligations.
5.2 Intellectual Property Rights; License to Athena. Subject to
Section 9.2, and except as set forth in this Section 5.2, Athena shall own and
have exclusive rights in all Patents and intellectual property (whether or not
patentable) relating to Active Compounds and the subject matter contained
therein and resulting from the Research Program during the Exclusivity Period
and thereafter so long as Athena continues to show Due Diligence for that
Target. Notwithstanding the foregoing, Athena acknowledges and agrees that
CombiChem reserves the right to assign or grant exclusive rights to any compound
to a third party collaborator who completes an act of invention with regard to
such compound to the extent CombiChem is obligated to do so under CombiChem's
existing contractual obligations and further provided that CombiChem has timely
(but in any event within *** after notification from Athena that such compound
shows In Vitro Activity) notified Athena in writing of such assignment or grant
and its designation as an unavailable compound. Athena shall be responsible for
filing, maintaining and prosecuting all Patents relating to Active Compounds at
its sole expense. Prior to the filing of any such Patent applications, CombiChem
shall assign to Athena or its designee all intellectual property rights it may
have in the Active Compounds and the subject matter claimed therein which are
necessary for the development and commercialization by Athena or its designee.
If Athena fails to so file, maintain or prosecute such Patent, CombiChem shall
have the right to request Athena to do so. If Athena elects not to file,
maintain or prosecute such Patent, on a country-by-country basis, CombiChem
shall have the right to take over such filing, maintenance or prosecution of
such Patent, at its sole expense, and, as a result, *** shall be entitled to
recover from the proceeds of any infringement action brought by CombiChem in any
such country (i) *** , and (ii) *** , with the remainder to be paid *** .
5.3 Structural Information. Neither Party shall disclose the
structure of any Active Compound to any Third Party without the other Party's
written permission, unless required to do so by law, in which case such Party
shall promptly notify the other Party of such required disclosure. If a subpoena
or other legal process concerning the same is served upon either Party, the
other Party shall cooperate with the Party served in any effort to contest the
validity of such subpoena or other legal process.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
10
12
5.4 Supply of Collaboration Compounds. Aliquots of at least ***
milligrams of any Collaboration Compound that has been synthesized will be
prepared and given to Athena. CombiChem shall replenish that amount upon
Athena's reasonable request. CombiChem shall maintain aliquots of any
Collaboration Compound that has been synthesized by CombiChem. CombiChem shall
also provide Athena with additional requirements of samples at CombiChem's cost.
6. RESEARCH MANAGEMENT COMMITTEE
The design, review and conduct of the Research Program will be
coordinated by the Research Management Committee, which will meet regularly on a
mutually-agreeable schedule. Each Party shall bear its own expenses related to
such meetings. The Research Management Committee may establish and amend or
revise the Research Plan as reasonable and necessary to reflect the scientific
progress and work performed under the Research Program, such amendments to be
mutually agreed to in writing by Athena and CombiChem. The Research Management
Committee will consist of an equal number of members from Athena and CombiChem
and will include appropriate representatives from Athena and CombiChem as
mutually agreed. The co-chairs of the Research Management Committee will
initially be the Vice President, Chemistry of CombiChem and the Vice President,
Research of Athena and subsequently may change as each Party determines for its
co-chair. Decisions of the Research Management Committee shall be by consensus.
If Athena elects not to file, maintain or prosecute such Patent, on a
country-by-country basis, CombiChem shall have the right to take over such
filing, maintenance or prosecution of such Patent, at its sole expense, and, as
a result, CombiChem shall be entitled to recover from the proceeds of any
infringement action brought by CombiChem in any such country (i) 200% of its
out-of-pocket costs, and (ii) 50% of the balance of the proceeds of such action,
with the remainder to be paid to Athena.
7. RESEARCH PERIOD; TERMINATION OF RESEARCH PROGRAM
7.1 Research Period: Option to Extend the Research Period. The
initial term of the Collaboration shall be the Research Period subject to
extension upon mutual agreement. To extend the Research Period, Athena must
notify CombiChem no later than ninety (90) days prior to the then-current
expiration date and the Parties shall negotiate in good faith the terms and
conditions of any such extension.
7.2 Termination of Research Program Upon Breach. The Research
Program and/or this Agreement may be terminated by a Party for the material
breach by the other Party as provided by Section 10.2.
7.3 Termination by Athena. Athena may terminate this Agreement
effective at any time after one (1) year from the Effective Date, in its sole
discretion, upon ninety (90) days' prior written notice. Athena may also
terminate any part of the Research Program directed at one or more of the
Collaboration Targets, also upon ninety (90) days' prior written notice, at any
time during the Collaboration, in which case the RMC shall reallocate the FTEs
affected to any of the other Collaboration Targets.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
11
13
8. CONSIDERATION
8.1 Project Initiation Fee. Athena shall pay CombiChem (a) within
ten (10) days following the Effective Date a non-refundable, noncontingent
project initiation fee of U.S. $1,333,333 in cash to initiate the Research
Program for the Initial Targets (Collaboration Targets *** ) and (b) upon the
designation of any Optional Target (Collaboration Targets *** ), a
non-refundable project initiation fee of U.S. *** per Optional Target (for a
total of *** ), payable upon the later of (i) the date of commencement of a
Research Program with respect to such Optional Target, or (ii) *** .
8.2 Equity Purchase. Elan International Services, Ltd. ("EIS"),
an Affiliate of Athena, shall purchase shares of Common Stock of CombiChem
pursuant to the terms of that certain Common Stock Purchase Agreement, dated as
of the Effective Date, by and between CombiChem and EIS (the "Stock Purchase
Agreement"). In the event that CombiChem closes an initial public offering of
its common stock at a sales price per share to the public (the "IPO Price")
which is less than $2.50 per share (on a pre-split basis), then, upon the
closing of such initial public offering, CombiChem shall issue to ImClone,
without further consideration other than the purchase price paid by ImClone
pursuant to the Stock Purchase Agreement, such additional number of shares of
CombiChem common stock equal to:
2,000,000
--------- = 1,000,000
Adjusted Price
wherein the "Adjusted Price" = the IPO Price X .80 if the IPO Price is less
than $2.50 per share. All shares of CombiChem common stock issued pursuant to
this Section 8.1 shall be deemed to be "Shares" within the meaning of the Stock
Purchase Agreement.
8.3 Program Funding.
(a) Research Support for Project Team. At all times
during the Research Period, Athena shall make payments to CombiChem for direct
research support for its Project Team, which shall consist of a minimum of five
(5) full time employees ("FTEs") of CombiChem, unless the RMC determines
otherwise. The total amount payable per FTE shall be U.S. *** . All payments for
direct research support shall be paid by Athena to CombiChem, quarterly in
advance, and adjusted as necessary in subsequent quarters, of such amounts as
are equal to the product of (i) the number of CombiChem FTEs (a minimum of five
(5) FTEs at all times unless the RMC determines otherwise) allocated to the
Research Program by the RMC for the calendar quarter to which each such payment
applies, multiplied by (ii) U.S. *** (i.e., the quarterly amount per Combichem
FTE on the basis of U.S. *** ). All such FTEs shall be CombiChem's employees.
Athena shall not be responsible for, and CombiChem shall indemnify and hold
Athena harmless from, any salary, benefits, or employment-related claims of any
kind asserted by CombiChem's employees.
(b) Expansion of Project Team. Athena may request that
CombiChem expand its Project Team during the Research Period in order to
accelerate work on Collaboration Targets and/or to add Optional Targets. In such
event, the RMC shall promptly confer as to the appropriate number of FTEs to be
added to the Project Team, at a cost to Athena of U.S. *** per FTE to be paid as
specified in Section 8.3(a).
8.4 Milestone Payments. Within thirty (30) days of the occurrence
of a development milestone triggered by the activities of Athena or its
Affiliates as shown on Appendix A, Athena shall pay CombiChem the related
milestone payment in U.S. dollars as set forth on Appendix A. Such payments
shall apply to any milestone reached by an Active Compound, Development Compound
or Product, whether the Target is within or outside the Collaboration.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
12
14
8.5 Royalties. During the Royalty Term, Athena will pay CombiChem
a *** of Net Sales of Products sold by Athena or its Affiliates in all countries
in the Territory. Each payment of royalties shall be accompanied by a report of
Net Sales of Products in sufficient detail to permit confirmation of the
accuracy of the royalty payment made.
8.6 Manner and Place of Payment. Royalty payments and reports for
Net Sales of Products shall be calculated in local currencies and reported for
each calendar quarter. All royalty payments owed under this Agreement shall be
made by wire transfer to the bank account to be designated by CombiChem within
sixty (60) days following the end of each such calendar quarter.
8.7 Records and Audit. During the term of this Agreement and for
a period of three (3) years thereafter, Athena shall keep complete and accurate
records pertaining to the sale or other disposition of Products in sufficient
detail to permit CombiChem to confirm the accuracy of all payments due
hereunder. CombiChem shall have the right to cause an independent certified
public accounting firm reasonably acceptable to Athena to audit such records to
confirm Athena's Net Sales for the preceding year. Any information obtained
during such audit shall be treated as Confidential Information. Such audits may
be exercised after reasonable notice during normal business hours of Athena no
more than once each year. CombiChem shall bear the full cost of such audit
unless such audit discloses a deficiency of the greater of *** or more than ***
from the amount of the Net Sales reported by Athena for such audited period. In
such case, Athena shall bear the reasonable cost of such audit.
8.8 Taxes. All income and other taxes levied on account of the
royalties and other payments accruing to CombiChem under this Agreement shall be
paid by CombiChem, including taxes levied thereon as income to CombiChem. If
provision is made in law or regulation for withholding, such tax shall be
deducted from the royalty or other payment made by Athena to the proper taxing
authority and a receipt of payment of the tax secured and promptly delivered to
CombiChem. Each Party agrees to assist the other Party reasonably in claiming
exemption from such deductions or withholdings under any double taxation or
similar agreement or treaty from time to time in force.
9. LICENSE GRANTS; OUTLICENSE
9.1 CombiChem License Grant to Athena. Subject to the terms and
conditions of this Agreement, CombiChem hereby grants to Athena an exclusive,
royalty-free, worldwide license, with the right to sublicense to use such
CombiChem Technology as is necessary to make, have made, use, have used, sell,
have sold, import and export Collaboration Compounds or Products in the
Territory. Such license shall remain exclusive (including as to CombiChem) in
relation to each Active Compound, Development Compound and/or Product so long as
Athena or its licensee continues to develop and commercialize such Active
Compound, Development Compound and/or Product against a Collaboration Target
with Due Diligence.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
13
15
9.2 Athena License Grant to CombiChem. Subject to Article 4 and
following the failure of Athena or its licensee to develop and commercialize
with Due Diligence an Active Compound, a Development Compound or Product, as the
case may be (collectively, and together with all Abandoned Compounds, "Returned
Compounds"), Athena shall grant to CombiChem a non-exclusive, royalty-free
license, with the right to sublicense, under those Athena Patents and know-how
which are resulting from the Research Program and related exclusively to the
Returned Compound, to make, have made, use, have used, sell, have sold, import
and export such Returned Compound in the Territory.
9.3 Athena Outlicense. Athena shall have the right to transfer,
assign or outlicense to a Third Party the Products or Patents covering the
Products, subject to CombiChem's right to receive (a) royalties as provided in
Appendix A, and (b) the percentage of the Third Party Payments set forth in
Appendix A. For purpose of this Section 9.3, "Third party Payments" shall mean
all payments **** *** , which shall include, but not be limited to, *** *** ***
. All Payments shall be made to CombiChem by wire transfer to such bank account
designated by CombiChem within five (5) business days after receipt by Athena or
its Affiliates of such Payments from the Third Party. As an express condition of
any such outlicense, any such licensee shall be required to agree in writing to
be bound by due diligence, royalty reporting and recordkeeping and inspection
provisions no less stringent than those contained in this Agreement. In
addition, CombiChem shall have the right to receive all audit reports relating
to sales of Products of Athena's licensees, and to cause Athena or its
Affiliates or successors to have an independent certified public accounting firm
(reasonably acceptable to Athena) audit such licensee's records on the same
terms as those specified in Section 8.6. Failure of such licensee to make any
milestone or royalty payment in respect of such Product shall not relieve Athena
of its obligations to make royalty and milestone payments to CombiChem
hereunder.
9.4 Rights to Inactive Compounds. Except for any Athena Compounds
(which remain proprietary to Athena), each of Athena and, subject to Athena's
Patent rights, CombiChem shall have rights to make, have made, use, have used,
sell, have sold, import and export Inactive Compounds or products containing
Inactive Compounds. Specifically, each party shall be free to screen Inactive
Compounds against any target other than the Collaboration Targets. In the event
that either Athena or CombiChem shall develop, market and/or sell, or enter into
a binding agreement with a Third Party to develop, market and/or sell, any
product containing the Inactive Compound as an active ingredient, then the other
Party hereto shall not be entitled to any payments, milestones, royalties, fees
or compensation of any kind.
10. TERM AND TERMINATION OF THE AGREEMENT
10.1 Term. The term of this Agreement shall commence upon the
Effective Date of this Agreement, and unless earlier terminated as provided in
this Agreement, shall expire on December 31, 2000.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
14
16
10.2 Termination by Athena or CombiChem. If either Party
materially breaches this Agreement and fails to remedy that breach within ninety
(90) days of receiving written notice thereof from the other Party, or enters
into any arrangement of composition with its creditors or goes into liquidation,
insolvency, bankruptcy, receivership or reorganization proceedings, whether
voluntarily or compulsorily which is not dismissed within ninety (90) days, then
the other Party may at any time, by notice in writing or by telefax, terminate
this Agreement. Within sixty (60) days following termination for any Research
Program and/or research related to any Target under this Agreement, the RMC
shall prepare a detailed, final written report to each Party, and provide any
remaining supply of compounds in synthesis to date, for each Target or Research
Program being terminated.
10.3 After Termination. Any termination of this Agreement or the
Research Program shall be without prejudice to the accrued rights of either
Party prior to the termination. In case of termination of this Agreement or the
Research Program pursuant to Section 10.2 above, all royalty, milestone, Payment
and confidentiality obligations set forth in Sections 8.1, 8.4, 8.5, 9.3, 9.4
and Articles 11 and 12 shall survive any such termination. Moreover, Athena
shall not be entitled to any refund of any payments made to CombiChem hereunder
upon the expiration of the term of this Agreement or earlier termination
pursuant to this Article 10.
10.4 Effect of Termination on Licensees. In the event or any
termination of this Agreement pursuant to this Article 10 where such termination
shall not have been caused by the action of inaction on the part of any
respective licensee of Athena or CombiChem, or by any breach by such licensee of
its obligations under its licensee from Athena or CombiChem, as appropriate,
such termination of this Agreement shall be without prejudice to the rights of
each non-breaching licensee and such licensee shall be deemed to be a direct
licensee hereunder.
11. CONFIDENTIAL INFORMATION
11.1 Nondisclosure. During the term of this Agreement and for a
period of *** *** after termination thereof, each Party will maintain all
Confidential Information in trust and confidence and will not disclose any
Confidential Information to any third party or use any Confidential Information
for any purpose except (i) as expressly authorized by this Agreement, (ii) as
required by law or court order, after as much advance notice as is practical to
the other Party, (iii) to its consultants, subcontractors or agents who need to
know to accomplish the purposes of this Agreement and who are bound by
equivalent written confidentiality obligations. Each Party may use the other
Party's Confidential Information only to the extent required to accomplish the
purposes of this Agreement. Each Party will use at least the same standard of
care as it uses to protect proprietary or confidential information of its own to
ensure that its Affiliates, employees, agents, consultants and other
representatives do not disclose or make any unauthorized use of the Confidential
Information. Each Party will promptly notify the other upon discovery of any
unauthorized use or disclosure of the Confidential Information.
11.2 Exceptions. Confidential Information shall not include any
information which the receiving Party can prove by competent evidence: (a) is
now, or hereafter becomes, through no act or failure to act on the part of the
receiving Party, generally known or available;
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
15
17
(b) is known by the receiving Party at the time of receiving such information,
as evidenced by its records; (c) is hereafter disclosed to the receiving Party
by a Third Party, as a matter of right and without restriction on disclosure;
(d) is independently developed by the receiving Party without the aid,
application or use of Confidential Information; or (e) is the subject of a
written permission to disclose provided by the disclosing Party.
12. PUBLICATIONS AND PUBLIC STATEMENTS
12.1 Publications. Without affecting obligations under Article 11
above, neither Party shall publish any information with respect to Collaboration
Compounds or Development Compound during the Exclusivity Period without the
prior written permission of the other Party. Such permission shall be approved
or disapproved within thirty (30) days of written request for permission unless
the other Party requests additional time (not to exceed ninety (90) days) for
the purpose of protecting its intellectual property position. Such permission
shall not be unreasonably withheld. The Party proposing to publish such
information shall give the other Party ninety (90) days prior written notice and
an opportunity to review such manuscript in order to determine the patentability
of the information contained therein.
12.2 Public Statements. Neither Party shall use the name of the
other Party in any public statement, prospectus, annual report or press release
or other public communication (collectively "Public Statements") without the
prior written approval of the other Party, which may not be unreasonably
withheld or delayed; provided, however, that both Parties shall endeavor in good
faith to give the other Party a minimum of two (2) business days to review such
Public Statements; provided, further, that, upon approval of any such Public
Statement, both Parties may disclose to Third Parties the information contained
in such Public Statement without the further approval of the other; and
provided, further, that if a Party does not approve such Public Statement,
either Party may still use the name of the other Party in any Public Statement
without the prior written approval of the other Party, if such Party is advised
by counsel that such disclosure is required to comply with applicable law.
13. INDEMNIFICATION
13.1 EACH PARTY HEREBY AGREES TO SAVE, DEFEND AND HOLD THE OTHER
PARTY AND ITS OFFICERS, DIRECTORS, EMPLOYEES, CONSULTANTS AND AGENTS HARMLESS
FROM AND AGAINST ANY AND ALL SUITS, CLAIMS, ACTIONS, DEMANDS, LIABILITIES,
EXPENSES AND LOSSES, INCLUDING REASONABLE LEGAL EXPENSES AND ATTORNEYS' FEES
("LOSSES") RESULTING DIRECTLY OR INDIRECTLY FROM THE INDEMNIFYING PARTY'S ACTS
OR OMISSIONS IN CONNECTION WITH THE MANUFACTURE, DEVELOPMENT, USE, HANDLING,
STORAGE, SALE OR OTHER DISPOSITION OF CHEMICAL AGENTS, COLLABORATION COMPOUNDS,
ACTIVE COMPOUNDS, DEVELOPMENT COMPOUNDS OR PRODUCTS BY SUCH PARTY, ITS
AFFILIATES OR LICENSEES except to the extent such Losses result from the
negligence, breach of this Agreement or willful misconduct of the Party claiming
a right of indemnification under this Article 13.
16
18
13.2 Infringement
(a) Subject to Section 13.2(c) below, Athena shall hold
CombiChem and its officers, directors, employees, consultants, and agents
harmless from and against any and all losses resulting from the infringement of
any Third Party's Patent issued as of the Effective Date due to the performance
by Athena or its Affiliates of any activity contemplated hereunder, including,
but not necessarily limited to, Athena's responsibilities under Section 2.2
above, developing Products, and selling Products.
(b) Subject to Section 13.2(c) below, CombiChem shall hold
Athena and its officers, directors, employees, consultants, and agents harmless
from and against any and all losses resulting from the infringement of any Third
Party's Patent issued as of the Effective Date due to the performance by
CombiChem of any activity contemplated hereunder, including, but not necessarily
limited to, CombiChem's responsibilities under Section 2.1 above.
(c) The indemnity provided in Sections 13.2(a) and 13.2(b)
above shall not apply where the loss is due to the breach by the indemnified
Party of a warranty made in Article 19.
13.3 Procedures. If either Party (the "Indemnified Party") seeks
indemnification under this Article 13, it shall inform the other Party (the
"Indemnifying Party") of a claim as soon as reasonably practicable after it
receives notice of the claim, shall permit the Indemnifying Party to assume
direction and control of the defense of the claim (including the right to settle
any claim brought against the Indemnified Party upon prior written consent,
which shall not be unreasonably withheld), and shall give reasonable cooperation
(at the expense of the Indemnifying Party) in the defense of such claim.
14. ASSIGNABILITY
This Agreement may not be assigned by either Party without the
prior written consent of the other Party, not to be unreasonably withheld;
provided, however, that either Party may assign this Agreement, in whole or in
part, to an Affiliate (which may, in Athena's case, include an *** or to a
successor of a Party in connection with the merger, consolidation or sale of all
or substantially all of such Party's assets or that portion of its business
pertaining to the subject matter of this Agreement (and upon doing so will
promptly notify the other Party in writing); provided that the assigning Party
remains fully liable as obligated hereunder.
15. DISPUTE RESOLUTION PROCEDURES
15.1 Senior Executives Discussions. If a decision on a matter
regarding the management of the Research Program as provided herein is not
reached by the RMC, the dispute will be resolved as set forth in Article 6
above. If a dispute arises between CombiChem and Athena with respect to matters
other than the management of the Research Program, either during or after the
Research Period, such dispute will be referred to the appropriate senior
management in the area of the dispute. If such senior management are unable to
resolve such dispute, such
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
17
19
dispute will be referred to the Chief Operating Officer of Elan and the Chief
Executive Officer of CombiChem. If such officers are unable to reach an
agreement within thirty (30) days following the initiation of discussions
between them, such dispute shall be settled by arbitration as described in
Section 15.2 below.
15.2 Binding Arbitration. If the parties have not been able to
resolve the dispute as provided in Section 15.1 above, the dispute shall be
finally settled by binding arbitration. Any arbitration hereunder shall be
conducted under rules of the American Arbitration Association. The arbitration
shall be conducted before three arbitrators chosen according to the following
procedure: each of the parties shall appoint one arbitrator and the two so
nominated shall choose the third. If the arbitrators chosen by the parties
cannot agree on the choice of the third arbitrator within a period of thirty
(30) days after their appointment, then the third arbitrator shall be appointed
by the Court of Arbitration of the American Arbitration Association. If
CombiChem brings an arbitration action, such arbitration shall occur in San
Francisco, California. If Athena brings an arbitration action, such arbitration
shall occur in San Diego, California. The arbitrators shall have the authority
to grant specific performance, and to allocate between the parties the costs of
arbitration in such equitable manner as they determine. The arbitral award (i)
shall be final and binding upon the parties; and (ii) may be entered in any
court of competent jurisdiction.
15.3 Injunctive Relief. Nothing contained in this Article 15 or
any other provisions of this Agreement shall be construed to limit or preclude a
Party from bringing any action in any court of competent jurisdiction for
injunctive or other provisional relief to compel the other Party to comply with
its obligations hereunder before or during the pendency of arbitration
proceedings.
16. NOTICES
Any notice required or permitted to be given hereunder shall be
deemed sufficient if sent by facsimile letter or overnight courier, or delivered
by hand to Athena or CombiChem at the respective addresses and facsimile numbers
as set forth below or at such other address and facsimile number as either Party
hereto may designate. If sent by facsimile letter, notice shall be deemed given
when the transmission is completed if the sender has a confirmed transmission
report. If a confirmed transmission report does not exist, then the notice will
be deemed given when the notice is actually received by the person to whom it is
sent. If delivered by overnight courier, notice shall be deemed given when it
has been signed for. If delivered by hand, notice shall be deemed given when
received.
if to CombiChem, to:
CombiChem, Inc.
0000 Xxxxxx Xxxxx Xx
Xxx Xxxxx, Xxxxxxxxxx 00000
Attention: President
Fax number: (000) 000-0000
18
20
with a copy to:
Xxxxxxx, Xxxxxxx & Xxxxxxxx LLP
000 Xxxxx Xxxx Xxxxxx, 00xx Xxxxx
Xxx Xxxxxxx, Xxxxxxxxxx 00000
Attention: Xxxxxx X. Xxxxx, Esq.
Fax number: (000) 000-0000
if to Athena, to:
Athena Neurosciences, Inc.
000 Xxxxxxx Xxxxxxxxx
Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000
Attn: General Counsel
Fax number: (000) 000-0000
17. SURVIVAL
The provisions of Sections 2.4, 5.1, 5.2, 5.3, 10.3, 10.4 and Articles
4, 8, 9, 11, 12, 13, 15, and this Article 17 shall survive termination of this
Agreement in addition to those provisions which by their terms survive.
18. ADDITIONAL TERMS
18.1 Entire Agreement. This Agreement and the Common Stock Purchase
Agreement constitute the entire understanding between the Parties with respect
to the subject matter hereto and supersedes and replaces all previous
negotiations, understandings, representations, writings and contract provisions
and rights relating hereof.
18.2 Amendment; No Waiver. No provision of this Agreement may be
amended, revoked or waived except by a writing signed and delivered by an
authorized officer of each Party. Any waiver on the part of either Party of any
breach or any fight or interest hereunder shall not imply the waiver of any
subsequent breach or waiver of any other right or interest.
18.3 Validity. The invalidity or unenforceability of any provision of
this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement, each of which shall remain in full force and
effect.
18.4 Headings. The descriptive headings are inserted for convenience of
reference only and are not intended to be part of or to affect the meaning of or
interpretation of this Agreement.
18.5 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which
together shall be deemed to be one and the same instrument.
19
21
18.6 Governing Law. This Agreement shall be governed by and construed
and enforced in accordance with the laws of the State of California, without
regard to conflicts of laws principles.
18.7 Further Assurances. At any time and from time to time after the
Effective Date, the Parties shall each do, execute, acknowledge and deliver, and
cause to be done, executed, acknowledged or delivered, all such further acts,
transfers, conveyances, or assignments as may be reasonably required to carry
out the transactions contemplated by this Agreement
19. REPRESENTATIONS AND WARRANTIES
19.1 Authorization. All action on the part of each of CombiChem, Athena
and their respective officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement and the performance of
all obligations of CombiChem, Athena and Athena, respectively, hereunder has
been taken. CombiChem represents that it has no present intention of materially
changing the manner in which it generally conducts its activities which are the
subject of the Collaboration.
19.2 Compliance with Other Instruments. The execution, delivery and
performance by CombiChem of this Agreement and the consummation of the Research
Program hereunder will not result in a violation of, or be in material conflict
with, or constitute a material default, under any agreement in existence as of
the Effective Date between CombiChem and its Third Party Collaborators. Subject
to Section 5.2 and except for the rights expressly reserved by CombiChem
therein, from the Effective Date until the expiration or termination of this
Agreement, CombiChem agrees that it shall not enter into any agreement with any
Third Party collaborator which would be in material conflict with, or cause a
default under, this Agreement.
19.3 Rights to Intellectual Property. Each Party warrants that it has
the power to grant all of the rights granted and make such required assignments,
and to assume all of the obligations required, under this Agreement. Under no
circumstances does CombiChem warrant to Athena that its rights in any Active
Compound, Development Compound or Products are exclusive to the extent such
Active Compound, Development Compound or Products may be covered under the
patent claims of Third Parties wherein such claims are not the direct result of
a collaboration between the Third Party and CombiChem.
20
22
IN WITNESS WHEREOF, the parties have executed this Agreement to be
effective as of the Effective Date.
COMBICHEM, INC. ATHENA NEUROSCIENCES, INC.
By: /s/ Xxxxxxx Xxxxx By: /s/ Illegible
---------------------- ---------------------
Its: President & CEO Its: Vice President & General Counsel
[SIGNATURE PAGE TO THE COLLABORATIVE
RESEARCH AND LICENSE AGREEMENT]
21
23
Appendix A
A. Milestones - Direct Marketing By Athena/Affiliates
Milestone Payments (in U.S. Dollars)
Milestone(1) Milestone Payment(2)
***
*** in:
*** ***
*** ***
*** ***
***
***
*** ***
*** ***
*** ***
***
***
*** ***
*** ***
*** ***
Total ***
(1) Based on Athena or its Affiliates having marketing responsibility for
Products
(2) Paid for each Compound which achieves the stated milestone
B. Outlicense By Athena/Affiliates
Royalty: *** of royalties received by Athena or its Affiliates, up to a
maximum of *** of all licensee net sales
Third Party Payments: *** of Third Party Payments received by Athena or
its Affiliates. In the case of outlicensing in *** a maximum of ***
(each), inclusive of any *** .
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
24
STRICTLY CONFIDENTIAL
MARCH 20, 1998
VIA FAX (000) 000-0000 AND
FEDERAL EXPRESS (000) 000-0000
Xxx X. XxXxxxxxx
Vice President, Business Development
CombiChem, Inc.
0000 Xxxxxx Xxxxx Xx
Xxx Xxxxx, XX 00000
Dear Xxx:
Pursuant to our recent discussions, this will confirm Athena's election to
substitute the [***] for the [***] target, as an Initial Target under our
Collaborative Research and License Agreement of October 15, 1997. You have
previously received Xxxx Xxxxx'x letter of March 3 to Xx. Xxxxx to that effect.
The [***] target now reverts to Related Target status under the agreement.
We understand that the [***] would be considered a separate target and is not
being substituted by Athena at this time. We have separately agreed that Athena
will have an option, for a [***] period from the date of CombiChem's signature
below, to take the [***] target into our collaboration. In return for that
option Athena will pay CombiChem a nonrefundable option fee of [***], payable
within three business days of our receipt of this letter countersigned by
CombiChem. That fee would be creditable against license fees, if any, associated
with selection of that target under the Agreement (i.e., as an Optional Target).
Of course, CombiChem will not take any action inconsistent with Athena's option
until its expiration or Athena's earlier written release of its option right in
that target.
Please let me know if you believe that more is required in order to accomplish
the formal substitution of the [***] target, so that we can address it
right away. If not, please indicate below CombiChem's acknowledgement of the
substitution and the option, and return an original signed copy to me. Xxxx is
fully up to date on this, and is anxious for the RMC to develop and implement a
research plan for this new target as soon as possible.
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
25
Xxx XxXxxxxxx STRICTLY CONFIDENTIAL
CombiChem
March 20, 1998
Thanks for your help on resolving this matter. Hope all goes well for you and
for CombiChem.
Best regards,
/s/ XXXXXX X. XXXXXX
Xxxxxx X. Xxxxxx
Vice President & General Counsel
ACKNOWLEDGED AND AGREED this 20th day of March, 1998.
COMBICHEM, INC.
By: /s/ XXX X. XXXXXXXXX
Xxx X. XxXxxxxxx
Vice President, Business Development
